Physician profile
Anna E Turner
NPI 1508361585
$2,828.09
in general payments reported to CMS, 2019-2025
27 companies · $865 in 2025
The $865 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $517 · 2023: $288 · 2024: $686 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.50 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $772.72 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $431.08 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Grifols USA, LLC | $175.56 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $150.49 | 2021-2025 | |
| Glaxosmithkline, LLC. | $141.87 | 2021-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $141.29 | 2022-2025 | Dupixent |
| Abbvie INC. | $131.24 | 2022 | |
| Pfizer INC. | $103.72 | 2022-2025 | |
| Alk-Abello, INC | $94.71 | 2022-2023 | Odactra, Ragwitek, Grastek |
| Mylan Specialty L.P. | $77.42 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $74.26 | 2022-2023 | Cuvitru |
| Cycle Pharmaceuticals INC | $72.53 | 2025 | Sajazir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.91 | 2021-2022 | |
| Amgen INC. | $60.11 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $56.04 | 2021-2024 | Orladeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $43.12 | 2025 | Cutaquig |
| Genzyme Corporation | $42.02 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $29.35 | 2021 | |
| Kaleo, INC. | $27.34 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $25.45 | 2022 | |
| Pharming Healthcare, INC. | $21.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.67 | 2025 | |
| Uswm, LLC | $15.01 | 2021 | |
| Hikma Pharmaceuticals USA | $14.80 | 2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $14.77 | 2021 | |
| Ionis Pharmaceuticals, INC. | $13.66 | 2025 | |
| Genentech USA, INC. | $10.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.